The coronavirus-19 (COVID-19) pandemic represents a huge hazard to patients experiencing hematopoietic foundational microorganism transplantation (HCT) or cell treatment. The American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Steering Committee expects to give drug store practice the executives proposals to how to progress clinical HCT or cell treatment drug store administrations utilizing telemedicine capacities in the inpatient and outpatient settings to keep up a comparable degree of clinical practice while limiting viral spread in a high-chance, immunocompromised populace. Also, the Steering Committee offers clinical administration suggestions for COVID-19 in HCT and cell treatment beneficiaries dependent on the quickly creating writing.
Editorial: Journal of Blood & Lymph
Editorial: Journal of Blood & Lymph
Research Article: Journal of Blood & Lymph
Research Article: Journal of Blood & Lymph
Short Communication: Journal of Blood & Lymph
Short Communication: Journal of Blood & Lymph
Review Article: Journal of Blood & Lymph
Review Article: Journal of Blood & Lymph
Editorial: Journal of Blood & Lymph
Editorial: Journal of Blood & Lymph
Posters & Accepted Abstracts: Cancer Science & Therapy
Posters & Accepted Abstracts: Cancer Science & Therapy
Posters-Accepted Abstracts: Cancer Science & Therapy
Posters-Accepted Abstracts: Cancer Science & Therapy
Posters & Accepted Abstracts: Journal of Nephrology & Therapeutics
Posters & Accepted Abstracts: Journal of Nephrology & Therapeutics
Posters & Accepted Abstracts: Journal of Nephrology & Therapeutics
Posters & Accepted Abstracts: Journal of Nephrology & Therapeutics
Scientific Tracks Abstracts: Journal of Nephrology & Therapeutics
Scientific Tracks Abstracts: Journal of Nephrology & Therapeutics
Accepted Abstracts: Journal of Nephrology & Therapeutics
Accepted Abstracts: Journal of Nephrology & Therapeutics
Journal of Blood & Lymph received 443 citations as per Google Scholar report